Background It is unknown how anemia influences the invasive management of patients with non-ST-segment elevation myocardial infarction (NSTEMI) and associated mortality. We investigated whether receipt of cardiac catheterization relates to 6-month death rates among patients with different severity of anemia.
Introduction
Anemia on presentation is common in patients hospitalized with acute myocardial infarction (AMI), and this condition is associated with an increased risk for dying and the development of nonfatal adverse events [1] [2] [3] [4] . Biologically, anemia has the potential to worsen the supplydemand mismatch in patients with underlying coronary artery disease [5, 6] . Anemia may also serve as a marker of comorbid conditions, especially conditions that predispose to bleeding [1, 2] , which may contribute to an increased risk of unfavorable outcomes [7] . However, anemia has been shown to be an independent predictor of adverse events in patients with underlying coronary disease, irrespective of the use of blood transfusions and multivariate-risk adjustment for additional comorbidities [8, 9] . It is also possible that AMI patients with anemia are managed differently than patients without anemia, which in turn may contribute to differences in prognosis. This is especially important in the invasive management of patients hospitalized with AMI, as balance has to be strived between performing invasive procedures in a population with a higher risk of adverse outcomes, such as those with anemia [9] [10] [11] [12] [13] , versus the potential benefits associated with coronary revascularization.
As there are limited data describing the relationship between anemia and the utilization of cardiac catheterization in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and hospital outcomes, we examined the association between anemia at the time of admission for NSTEMI and cardiac catheterization use during hospitalization, and how the use of cardiac catheterization relates to 6-month death rates among patients with varying severity of anemia. Data from the populationbased Worcester Heart Attack Study (WHAS) were used for purposes of this investigation [11] [12] [13] .
Methods

Study population
The WHAS is a population-based clinical/epidemiological investigation examining changing trends in the descriptive epidemiology of AMI in adult residents of the Worcester (Massachusetts, USA) metropolitan area [14] [15] [16] . Medical records of patients hospitalized for possible AMI at all 11 Greater Worcester medical centers in five biennial periods between 1997 and 2005 were retrospectively reviewed. The presence of AMI was validated according to standardized criteria including the presence of at least two of the following three factors: presence of symptoms consistent with AMI, serial electrocardiographic changes during hospitalization, and increases in serum cardiac enzyme levels above the upper limit of normal at each participating hospital's laboratory [17] .
Consistent with American College of Cardiology/American Heart Association guidelines [18, 19] , we considered NSTEMI to be present when there was absence of ST segment elevation more than or equal to 1 mm, or a new, or presumably new pattern of left bundle branch block on the admission electrocardiography. Of the 5385 patients hospitalized with a validated AMI during the five study years between 1997 and 2005 (1997, 1999, 2001, 2003 , and 2005), we restricted our study sample to those with NSTEMI (n = 3314) so that patients would have similar patterns and indications for invasive disease management.
We excluded patients who had either a known terminal illness as recorded in the medical record by treating clinicians (n = 23), who died during the first 48 h of hospitalization (n = 100), or who were discharged within 24 h after hospital arrival (n = 63) because the treatment of these patients may not have been intended to prolong survival [1] . We also excluded patients who were transferred out of the hospital after 24 h of admission (n = 262) as we could not follow their subsequent utilization of invasive cardiac procedures, and patients who were not initially admitted to a percutaneous coronary intervention (PCI)-capable facility (n = 186); the latter patients were excluded because the likelihood of these patients undergoing invasive management for NSTEMI may be intrinsically different from those admitted to PCI-capable facilities. We also excluded 46 patients with missing admission hematocrit or cardiac catheterization data. Our final sample consisted of 2634 patients with independently validated NSTEMI who were treated at three PCI-capable Greater Worcester hospitals during the years under study.
Data collection
Demographic, medical history, and clinical characteristics, laboratory findings, and receipt of invasive coronary procedures during hospitalization were abstracted from hospital medical records by trained nurse and physician reviewers [20] . The random reabstraction of data occurred on an ongoing basis for quality assurance, with discrepancies of data resolved by consensus at regular meetings by all members of the data abstraction team. When a patient was transferred from one hospital facility to another within 24 h of the index hospital admission, information on procedures performed in the second facility, such as cardiac catheterization, PCI, or coronary artery bypass surgery (CABG), as well as the development of hospital complications, including hemorrhage and death, were captured and adjudicated as part of the same AMI hospitalization. Bleeding episodes were categorized as either major (requiring transfusion) or minor (not requiring transfusion).
Anemia at hospital admission
Anemia and its severity on admission were measured using hematocrit levels documented in hospital medical records. The first hematocrit measurement taken within 24 h after hospital admission was categorized as less than or equal to 30% (moderate-to-severe anemia), 30.1-39.0% (mild anemia), and more than 39.0% (no anemia). This categorization differentiates between patients without clinical anemia and those with mild to significant degrees of anemia. As we did not find significant differences between men and women in the receipt of cardiac catheterization when the data were stratified according to various hematocrit categories, we defined anemia using a single cut-off hematocrit value of less than or equal to 39% for both men and women, which is similar to the hemoglobin cutoff for anemia in men based on World Health Organization criteria [21] .
Outcomes
The use of cardiac catheterization and subsequent coronary revascularization (PCI or CABG) during hospitalization was abstracted from patients' medical records (including catheterization reports). All patients discharged from Greater Worcester hospitals after AMI were followed through a statewide and national search of death certificates to determine their vital status. In this study, we examined 6-month all-cause death rates from the time of hospital admission.
Data analysis
Differences in baseline demographic and clinical characteristics among patients in relation to severity of anemia were compared using the w 2 test for categorical variables and analysis of variance for continuous variables, and tested for trends. We estimated odds ratios (ORs) and accompanying 95% confidence intervals (CIs) of patients undergoing cardiac catheterization in relation to severity of anemia, with patients without anemia serving as the referent category. We controlled for confounding using multivariate adjustment and evaluated as potential confounders the variables listed in Table 1 . Forward stepwise logistic regression analysis was used for variable selection with model entry criteria of P value of less than 0.2. The final model adjusted for clustering of patients by hospital of admission and by year of hospital admission for AMI.
To determine whether cardiac catheterization use was associated with the risk of dying at 6 months after hospital admission among patients with different severity of anemia, we conducted a propensity-matched analysis in an attempt to minimize the potential effect of selection bias (e.g. healthier patients are more likely to undergo procedures when compared with sicker patients) [22, 23] . A nonparsimonious logistic regression model including the patient's baseline demographic and clinical characteristics computed each patient's probability (or propensity) of undergoing cardiac catheterization during hospitalization. Patients who underwent cardiac catheterization were matched 1 : 1 to those who did not, based on the propensity of cardiac catheterization [24] . We then examined the matched cohort for balance of characteristics between the catheterization and the noncatheterization groups. Conditional logistic regression adjusted for differences in the hospital use of aspirin, plavix, and heparin, and we determined the effects of cardiac catheterization on 6-month postadmission mortality risk for all patients and in the three anemia subgroups defined by their admission hematocrit values.
Results
In general, patients with anemia were older, more likely to be female, to have a do-not-resuscitate order, history of aspirin use, and additional comorbid conditions present compared with patients without anemia ( Table 1 ). These differences were mostly larger for patients with moderateto-severe anemia versus those with mild anemia, with the exception of the likelihood of being a female or having a history of angina, myocardial infarction, hypertension, or aspirin use, which were higher for patients with mild anemia. In contrast, patients without anemia were more likely to be current smokers and have hyperlipidemia than patients with moderate-to-severe anemia (Table 1) . At the time of AMI presentation, patients with anemia had, on average, lower systolic blood pressure, higher serum creatinine levels and platelet counts, a higher frequency of either major or minor bleeding episodes, and were more likely to have heart failure than patients without anemia; trends were stronger among patients with moderate-to-severe anemia (Table 1 ; P < 0.05). The use of cardiac catheterization during hospitalization for NSTEMI was significantly higher in patients without anemia (58.9%) compared with those with mild anemia (39.5%) and moderate-to-severe anemia (25.6%; P < 0.01 for difference and trend). After risk adjustment using forward stepwise regression modeling, differences in cardiac catheterization usage remained significantly lower in patients with anemia; patients with mild anemia had a 20% lower odds [adjusted OR (AOR) = 0.79; 95% CI: 0.67-0.95] and patients with moderate-to-severe anemia had a 55% lower odds (AOR = 0.45; 95% CI: 0.42-0.49) of receiving cardiac catheterization compared with patients without anemia. Among patients who underwent cardiac catheterization, rates of PCI were unrelated to the severity of anemia (P = 0.18), whereas the rates of CABG were significantly higher in patients with moderate-tosevere anemia compared with patients with mild or no anemia (P = 0.02, Fig. 1 ).
Patients who underwent cardiac catheterization were younger, more likely to be male, a current smoker, and to have a history of angina, PCI, aspirin use, and hyperlipidemia (Table 2) . On admission, they had, on average, lower resting heart rate and creatinine levels and higher systolic blood pressure and hematocrit levels. Patients who underwent cardiac catheterization were also more likely to have received aspirin, clopidogrel, and heparin during their hospital stay. In contrast, patients who did not undergo cardiac catheterization were more likely to have a do-not-resuscitate order and comorbidities that included myocardial infarction, diabetes, stroke, bleeding, and peptic ulcer disease. They were also more likely to have a higher white count, heart failure, and major and minor bleeding on the day of admission ( Table 2) .
The logistic regression model to generate the propensity score for cardiac catheterization had excellent predictive discrimination with a c-index of 0.85. On the basis of the propensity score, 44% of catheterization patients (n = 549) were matched with noncatheterization controls (n = 549). Examination of this matched cohort (Table 3) showed successful matching, with balance of the baseline characteristics between patients who underwent cardiac catheterization and those who did not, with the exception of hospital use of aspirin, clopidogrel, and heparin. After adjusting for hospital use of aspirin, clopidogrel, and heparin with conditional logistic regression modeling, cardiac catheterization was associated with a 52% reduction in 6-month mortality in the full matched sample (n = 1098; AOR = 0.48; 95% CI: 0.32-0.71). The effect of cardiac catheterization differed according to severity of anemia. Cardiac catheterization was associated with reductions in 6-month mortality only in patients without anemia (n = 525, AOR = 0.26; 95% CI: 0.09-0.79) but not among patients with mild anemia (n = 503, AOR = 0.55; 95% CI: 0.25-1.23). Small sample size (n = 70) rendered data inconclusive for patients with moderate-to-severe anemia.
Discussion
In this observational study in residents of a large Central New England community, severity of anemia at the time of hospital admission for NSTEMI was associated with lower use of cardiac catheterization. However, the use of cardiac catheterization was associated with lower 6-month death rates only in patients without anemia.
Cardiac catheterization is currently a standard procedure for most patients with confirmed NSTEMI whose management goal is to prolong life and decrease the occurrence of cardiac-related symptoms [18, 25, 26] . In this study, 59% of patients without anemia underwent cardiac catheterization, which is comparable with the national rate of 58% reported by the OASIS investigators in 1995-1996 [27] , and of 62% in the CRUSADE quality improvement initiative in 2000-2002 [26] . However, we observed cardiac catheterization rates of 40% among patients with mild anemia and 26% among patients with moderate-to-severe anemia. These rates are clearly lower than national patterns and have not been reported in the recent literature. On the basis of the results of our multivariable-adjusted analysis, these lower catheterization rates cannot be primarily explained by the demographic and clinical profile of patients with anemia and suggest that clinicians are less likely to perform this diagnostic procedure in patients with anemia, a trend that increased with higher severity of anemia. Frequency of coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG)] among patients who underwent cardiac catheterization according to severity of anemia. Among patients who underwent cardiac catheterization, the rates of PCI (lighter gray bars) were unrelated to the severity of anemia (P = 0.18), whereas the rates of CABG (darker gray bars) were significantly higher in patients with moderate-to-severe anemia when compared with patients with mild or no anemia (P = 0.02).
A number of studies have highlighted the detrimental associations between bleeding and the risk of dying in patients hospitalized with AMI and anemia who undergo PCI compared with those without anemia [10, 28] , especially in patients with multivessel disease or incomplete revascularization [13] . However, data are lacking from randomized controlled trials to assess whether patients with anemia would derive any benefits from invasive management or whether a more aggressive treatment strategy may be associated with potential harm. The results of this study build on the existing literature by showing that, although no harmful outcomes were associated with cardiac catheterization use in NSTEMI patients with anemia, a gradient exists in the potential mortality reductions associated with cardiac catheterization use, in which significant benefits were found only in patients without anemia on admission, and a lesser and nonsignificant effect in patients with mild anemia. Several reasons can explain the lesser benefits of invasive management in patients with anemia. For example, higher risks of procedural-related complications and adverse outcomes have been found in patients with anemia who undergo PCI or CABG [9, 10, 12, [29] [30] [31] [32] . Patients with anemia also have lower reserve to tolerate bleeding complications, and bleeding risks are increased in patients undergoing an invasive management strategy [9, 33] . In addition, the underlying etiological factors leading to anemia may have conferred a worse prognosis in these patients, irrespective of their underlying coronary disease and revascularization status.
Considerable literature suggests that the higher risks of procedural-related complications and adverse outcomes in patients with anemia who undergo PCI or CABG cannot be overlooked and needed to be balanced against the potential benefits associated with coronary revascularization [9, 10, 12, [29] [30] [31] [32] . This study supports these concerns; we observed a higher likelihood of a bleeding history and rates of bleeding on hospital admission among patients with anemia compared with those without anemia. Our results also suggest that the lesser benefits derived from an invasive management strategy may be one of the potential mechanisms associated with an increased risk of dying and the development of nonfatal adverse events in anemic patients with AMI that have been previously noted in the literature [1, 28, 34, 35] .
Study strengths and limitations
Despite the use of propensity matching, which allowed us to control for several potentially confounding prognostic factors, the effect of selection bias may still exist given the observational nature of this study. This bias may be Cardiac catheterization use and anemia Wu et al. 321 attributed in part to the older age of our study population, especially of the severely anemic patients, with high frailty indices [36, 37] , which could influence the physician's selection of an invasive treatment strategy and impact the outcome of elderly patients. Although we controlled for an extensive list of comorbidities that may partially capture frailty [36, 37] , other factors such as physical function and capacity to perform daily activities were not collected in our review of data from hospital medical records. As such, the potential benefits that we found related to cardiac catheterization on 6-month mortality may be overestimated. In addition, although we collected a considerable amount of detailed clinical information, we did not have data available on the use of blood transfusions during hospitalization and, therefore, cannot account for the potential impact of blood transfusion use on patient outcomes. The generalizability of our findings may also be limited to the extent of the characteristics of our study population that were matched for the propensity analysis (e.g. we did not have sufficient sample size to obtain meaningful results in patients with moderate-to-severe anemia).
Our study also has several strengths. The WHAS is population-based and reflects real-life practice patterns that enhance the applicability of our results to daily practice. The utilization of cardiac catheterization in our patient population was comparable with catheterization rates observed in other large observational studies and our findings are potentially generalizable to regional NSTE-MI treatment practice patterns of PCI-capable hospitals [26, 27] .
Conclusion
Severity of anemia at the time of admission for NSTEMI is associated with lower utilization of cardiac catheterization during hospitalization. However, catheterization use was associated with a decreased risk of dying at 6 months postadmission only in patients without anemia. Randomized controlled trials are needed to confirm the findings of this observational study. In addition, further studies are needed to determine the benefit-to-risk ratios of invasive therapeutic strategies in NSTEMI, and optimal medication regimens, for patients with moderate-to-severe degrees of anemia.
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